Reata Pharmaceuticals, Inc. (RETA) Stock Competitors & Peer Comparison
See (RETA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RETA | $172.36 | +0.02% | 6.6B | -66.29 | -$2.60 | N/A |
| VRTX | $485.39 | -2.24% | 123.2B | 25.79 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $664.52 | -0.51% | 68.5B | 14.56 | $45.63 | +0.55% |
| ARGX | $877.62 | -3.50% | 54.6B | 79.21 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $298.76 | -4.49% | 39.9B | 53.83 | $5.55 | N/A |
| RVMD | $186.88 | -2.22% | 39.7B | -26.43 | -$7.07 | N/A |
| RVMDW | $9.36 | -4.65% | 39.1B | -2.26 | -$4.15 | N/A |
| ONC | $298.70 | -1.36% | 31.9B | 66.82 | $4.47 | N/A |
Stock Comparison
RETA vs VRTX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, VRTX has a market cap of 123.2B. Regarding current trading prices, RETA is priced at $172.36, while VRTX trades at $485.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas VRTX's P/E ratio is 25.79. In terms of profitability, RETA's ROE is +0.47%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, RETA is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check VRTX's competition here
RETA vs VRNA Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RETA is priced at $172.36, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RETA's ROE is +0.47%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, RETA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check VRNA's competition here
RETA vs REGN Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, REGN has a market cap of 68.5B. Regarding current trading prices, RETA is priced at $172.36, while REGN trades at $664.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas REGN's P/E ratio is 14.56. In terms of profitability, RETA's ROE is +0.47%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RETA is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check REGN's competition here
RETA vs ARGX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ARGX has a market cap of 54.6B. Regarding current trading prices, RETA is priced at $172.36, while ARGX trades at $877.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ARGX's P/E ratio is 79.21. In terms of profitability, RETA's ROE is +0.47%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, RETA is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ARGX's competition here
RETA vs SGEN Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RETA is priced at $172.36, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RETA's ROE is +0.47%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RETA is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check SGEN's competition here
RETA vs ALNY Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ALNY has a market cap of 39.9B. Regarding current trading prices, RETA is priced at $172.36, while ALNY trades at $298.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ALNY's P/E ratio is 53.83. In terms of profitability, RETA's ROE is +0.47%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, RETA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ALNY's competition here
RETA vs RVMD Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RVMD has a market cap of 39.7B. Regarding current trading prices, RETA is priced at $172.36, while RVMD trades at $186.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RVMD's P/E ratio is -26.43. In terms of profitability, RETA's ROE is +0.47%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, RETA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check RVMD's competition here
RETA vs RVMDW Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RVMDW has a market cap of 39.1B. Regarding current trading prices, RETA is priced at $172.36, while RVMDW trades at $9.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RVMDW's P/E ratio is -2.26. In terms of profitability, RETA's ROE is +0.47%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, RETA is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check RVMDW's competition here
RETA vs ONC Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ONC has a market cap of 31.9B. Regarding current trading prices, RETA is priced at $172.36, while ONC trades at $298.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ONC's P/E ratio is 66.82. In terms of profitability, RETA's ROE is +0.47%, compared to ONC's ROE of +0.12%. Regarding short-term risk, RETA is less volatile compared to ONC. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ONC's competition here
RETA vs MRNA Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MRNA has a market cap of 27.1B. Regarding current trading prices, RETA is priced at $172.36, while MRNA trades at $68.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MRNA's P/E ratio is -8.38. In terms of profitability, RETA's ROE is +0.47%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, RETA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MRNA's competition here
RETA vs ROIV Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ROIV has a market cap of 25.9B. Regarding current trading prices, RETA is priced at $172.36, while ROIV trades at $35.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ROIV's P/E ratio is -36.97. In terms of profitability, RETA's ROE is +0.47%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, RETA is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ROIV's competition here
RETA vs INSM Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, RETA is priced at $172.36, while INSM trades at $115.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas INSM's P/E ratio is -20.11. In terms of profitability, RETA's ROE is +0.47%, compared to INSM's ROE of -1.30%. Regarding short-term risk, RETA is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check INSM's competition here
RETA vs INCY Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, INCY has a market cap of 23.3B. Regarding current trading prices, RETA is priced at $172.36, while INCY trades at $116.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas INCY's P/E ratio is 15.69. In terms of profitability, RETA's ROE is +0.47%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RETA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check INCY's competition here
RETA vs UTHR Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, UTHR has a market cap of 23.2B. Regarding current trading prices, RETA is priced at $172.36, while UTHR trades at $547.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas UTHR's P/E ratio is 20.19. In terms of profitability, RETA's ROE is +0.47%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RETA is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check UTHR's competition here
RETA vs BNTX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, RETA is priced at $172.36, while BNTX trades at $91.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BNTX's P/E ratio is -19.80. In terms of profitability, RETA's ROE is +0.47%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, RETA is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BNTX's competition here
RETA vs BGNE Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RETA is priced at $172.36, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RETA's ROE is +0.47%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, RETA is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BGNE's competition here
RETA vs DNA-WT Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RETA is priced at $172.36, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RETA's ROE is +0.47%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, RETA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check DNA-WT's competition here
RETA vs NBIX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, NBIX has a market cap of 17.8B. Regarding current trading prices, RETA is priced at $172.36, while NBIX trades at $177.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas NBIX's P/E ratio is 25.59. In terms of profitability, RETA's ROE is +0.47%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, RETA is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check NBIX's competition here
RETA vs GMAB Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, GMAB has a market cap of 17.8B. Regarding current trading prices, RETA is priced at $172.36, while GMAB trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas GMAB's P/E ratio is 20.86. In terms of profitability, RETA's ROE is +0.47%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, RETA is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check GMAB's competition here
RETA vs BBIO Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BBIO has a market cap of 16.8B. Regarding current trading prices, RETA is priced at $172.36, while BBIO trades at $85.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BBIO's P/E ratio is -22.97. In terms of profitability, RETA's ROE is +0.47%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, RETA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BBIO's competition here
RETA vs ASND Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ASND has a market cap of 16.8B. Regarding current trading prices, RETA is priced at $172.36, while ASND trades at $270.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ASND's P/E ratio is -111.76. In terms of profitability, RETA's ROE is +0.47%, compared to ASND's ROE of -56.42%. Regarding short-term risk, RETA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ASND's competition here
RETA vs JAZZ Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, JAZZ has a market cap of 15.3B. Regarding current trading prices, RETA is priced at $172.36, while JAZZ trades at $243.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas JAZZ's P/E ratio is 18.96. In terms of profitability, RETA's ROE is +0.47%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, RETA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check JAZZ's competition here
RETA vs EXEL Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, EXEL has a market cap of 14.2B. Regarding current trading prices, RETA is priced at $172.36, while EXEL trades at $56.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas EXEL's P/E ratio is 16.92. In terms of profitability, RETA's ROE is +0.47%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, RETA is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check EXEL's competition here
RETA vs KRTX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RETA is priced at $172.36, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RETA's ROE is +0.47%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RETA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check KRTX's competition here
RETA vs MDGL Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, RETA is priced at $172.36, while MDGL trades at $536.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MDGL's P/E ratio is -41.93. In terms of profitability, RETA's ROE is +0.47%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, RETA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MDGL's competition here
RETA vs AXSM Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, AXSM has a market cap of 12B. Regarding current trading prices, RETA is priced at $172.36, while AXSM trades at $233.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas AXSM's P/E ratio is -61.04. In terms of profitability, RETA's ROE is +0.47%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, RETA is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check AXSM's competition here
RETA vs SMMT Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, SMMT has a market cap of 11.8B. Regarding current trading prices, RETA is priced at $172.36, while SMMT trades at $15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas SMMT's P/E ratio is -9.53. In terms of profitability, RETA's ROE is +0.47%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, RETA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check SMMT's competition here
RETA vs BMRN Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, RETA is priced at $172.36, while BMRN trades at $59.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BMRN's P/E ratio is 28.42. In terms of profitability, RETA's ROE is +0.47%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, RETA is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BMRN's competition here
RETA vs RNAM Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RETA is priced at $172.36, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RETA's ROE is +0.47%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RETA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check RNAM's competition here
RETA vs TECH Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, RETA is priced at $172.36, while TECH trades at $71.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TECH's P/E ratio is 36.75. In terms of profitability, RETA's ROE is +0.47%, compared to TECH's ROE of +0.05%. Regarding short-term risk, RETA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check TECH's competition here
RETA vs KRYS Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, KRYS has a market cap of 10.8B. Regarding current trading prices, RETA is priced at $172.36, while KRYS trades at $365.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas KRYS's P/E ratio is 48.91. In terms of profitability, RETA's ROE is +0.47%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RETA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check KRYS's competition here
RETA vs ARWR Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ARWR has a market cap of 10.8B. Regarding current trading prices, RETA is priced at $172.36, while ARWR trades at $76.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ARWR's P/E ratio is -35.53. In terms of profitability, RETA's ROE is +0.47%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, RETA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ARWR's competition here
RETA vs CYTK Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CYTK has a market cap of 10.6B. Regarding current trading prices, RETA is priced at $172.36, while CYTK trades at $84.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CYTK's P/E ratio is -14.56. In terms of profitability, RETA's ROE is +0.47%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, RETA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CYTK's competition here
RETA vs ABVX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ABVX has a market cap of 10.3B. Regarding current trading prices, RETA is priced at $172.36, while ABVX trades at $139.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ABVX's P/E ratio is -73.17. In terms of profitability, RETA's ROE is +0.47%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RETA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ABVX's competition here
RETA vs CORT Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CORT has a market cap of 9.9B. Regarding current trading prices, RETA is priced at $172.36, while CORT trades at $91.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CORT's P/E ratio is 262.51. In terms of profitability, RETA's ROE is +0.47%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RETA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CORT's competition here
RETA vs KYMR Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, KYMR has a market cap of 9.8B. Regarding current trading prices, RETA is priced at $172.36, while KYMR trades at $119.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas KYMR's P/E ratio is -33.81. In terms of profitability, RETA's ROE is +0.47%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, RETA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check KYMR's competition here
RETA vs IONS Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, IONS has a market cap of 9.6B. Regarding current trading prices, RETA is priced at $172.36, while IONS trades at $58.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas IONS's P/E ratio is -33.87. In terms of profitability, RETA's ROE is +0.47%, compared to IONS's ROE of -0.59%. Regarding short-term risk, RETA is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check IONS's competition here
RETA vs RXDX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RETA is priced at $172.36, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RETA's ROE is +0.47%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RETA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check RXDX's competition here
RETA vs NUVL Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, RETA is priced at $172.36, while NUVL trades at $123.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas NUVL's P/E ratio is -21.78. In terms of profitability, RETA's ROE is +0.47%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RETA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check NUVL's competition here
RETA vs HALO Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, HALO has a market cap of 9B. Regarding current trading prices, RETA is priced at $172.36, while HALO trades at $76.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas HALO's P/E ratio is 16.49. In terms of profitability, RETA's ROE is +0.47%, compared to HALO's ROE of +1.26%. Regarding short-term risk, RETA is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check HALO's competition here
RETA vs CRNX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, RETA is priced at $172.36, while CRNX trades at $83.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CRNX's P/E ratio is -16.29. In terms of profitability, RETA's ROE is +0.47%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RETA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CRNX's competition here
RETA vs TGTX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TGTX has a market cap of 8.7B. Regarding current trading prices, RETA is priced at $172.36, while TGTX trades at $57.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TGTX's P/E ratio is 19.63. In terms of profitability, RETA's ROE is +0.47%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, RETA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check TGTX's competition here
RETA vs IMGN Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RETA is priced at $172.36, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RETA's ROE is +0.47%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RETA is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check IMGN's competition here
RETA vs ALKS Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ALKS has a market cap of 8.7B. Regarding current trading prices, RETA is priced at $172.36, while ALKS trades at $51.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ALKS's P/E ratio is 54.67. In terms of profitability, RETA's ROE is +0.47%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, RETA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ALKS's competition here
RETA vs IBRX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, IBRX has a market cap of 8.6B. Regarding current trading prices, RETA is priced at $172.36, while IBRX trades at $8.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas IBRX's P/E ratio is -25.69. In terms of profitability, RETA's ROE is +0.47%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, RETA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check IBRX's competition here
RETA vs PTGX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, RETA is priced at $172.36, while PTGX trades at $131.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas PTGX's P/E ratio is -72.61. In terms of profitability, RETA's ROE is +0.47%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, RETA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check PTGX's competition here
RETA vs PCVX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, RETA is priced at $172.36, while PCVX trades at $58.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas PCVX's P/E ratio is -8.46. In terms of profitability, RETA's ROE is +0.47%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, RETA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check PCVX's competition here
RETA vs BPMC Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RETA is priced at $172.36, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RETA's ROE is +0.47%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, RETA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check BPMC's competition here
RETA vs APGE Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, RETA is priced at $172.36, while APGE trades at $133.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas APGE's P/E ratio is -30.87. In terms of profitability, RETA's ROE is +0.47%, compared to APGE's ROE of -0.33%. Regarding short-term risk, RETA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check APGE's competition here
RETA vs CERE Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RETA is priced at $172.36, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CERE's P/E ratio is -16.47. In terms of profitability, RETA's ROE is +0.47%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RETA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check CERE's competition here
RETA vs IMVT Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, RETA is priced at $172.36, while IMVT trades at $39.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas IMVT's P/E ratio is -14.87. In terms of profitability, RETA's ROE is +0.47%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, RETA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check IMVT's competition here
RETA vs RYTM Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RYTM has a market cap of 7.4B. Regarding current trading prices, RETA is priced at $172.36, while RYTM trades at $108.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RYTM's P/E ratio is -34.63. In terms of profitability, RETA's ROE is +0.47%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, RETA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check RYTM's competition here
RETA vs MTSR Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RETA is priced at $172.36, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RETA's ROE is +0.47%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, RETA is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MTSR's competition here
RETA vs LQDA Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, LQDA has a market cap of 7.2B. Regarding current trading prices, RETA is priced at $172.36, while LQDA trades at $77.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas LQDA's P/E ratio is 581.79. In terms of profitability, RETA's ROE is +0.47%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, RETA is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check LQDA's competition here
RETA vs PTCT Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, PTCT has a market cap of 7B. Regarding current trading prices, RETA is priced at $172.36, while PTCT trades at $84.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas PTCT's P/E ratio is -36.42. In terms of profitability, RETA's ROE is +0.47%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, RETA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check PTCT's competition here
RETA vs PRAX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, RETA is priced at $172.36, while PRAX trades at $324.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas PRAX's P/E ratio is -24.31. In terms of profitability, RETA's ROE is +0.47%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, RETA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check PRAX's competition here
RETA vs MRUS Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RETA is priced at $172.36, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RETA's ROE is +0.47%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, RETA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check MRUS's competition here
RETA vs SRRK Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, SRRK has a market cap of 6.8B. Regarding current trading prices, RETA is priced at $172.36, while SRRK trades at $56.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas SRRK's P/E ratio is -15.80. In terms of profitability, RETA's ROE is +0.47%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, RETA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check SRRK's competition here
RETA vs ACLX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RETA is priced at $172.36, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RETA's ROE is +0.47%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RETA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check ACLX's competition here
RETA vs COGT Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, COGT has a market cap of 6.6B. Regarding current trading prices, RETA is priced at $172.36, while COGT trades at $38.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas COGT's P/E ratio is -18.42. In terms of profitability, RETA's ROE is +0.47%, compared to COGT's ROE of -0.83%. Regarding short-term risk, RETA is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check COGT's competition here
RETA vs CGON Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, RETA is priced at $172.36, while CGON trades at $75.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CGON's P/E ratio is -32.29. In terms of profitability, RETA's ROE is +0.47%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RETA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CGON's competition here
RETA vs LGND Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, LGND has a market cap of 6.5B. Regarding current trading prices, RETA is priced at $172.36, while LGND trades at $316.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas LGND's P/E ratio is 38.68. In terms of profitability, RETA's ROE is +0.47%, compared to LGND's ROE of +0.16%. Regarding short-term risk, RETA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check LGND's competition here
RETA vs CNTA Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, RETA is priced at $172.36, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CNTA's P/E ratio is -22.63. In terms of profitability, RETA's ROE is +0.47%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RETA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check CNTA's competition here
RETA vs MIRM Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, RETA is priced at $172.36, while MIRM trades at $122.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MIRM's P/E ratio is -8.97. In terms of profitability, RETA's ROE is +0.47%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, RETA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MIRM's competition here
RETA vs BLTE Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, RETA is priced at $172.36, while BLTE trades at $149.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas BLTE's P/E ratio is -79.86. In terms of profitability, RETA's ROE is +0.47%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, RETA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check BLTE's competition here
RETA vs SYRE Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, SYRE has a market cap of 5.9B. Regarding current trading prices, RETA is priced at $172.36, while SYRE trades at $97.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas SYRE's P/E ratio is -46.99. In terms of profitability, RETA's ROE is +0.47%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, RETA is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check SYRE's competition here
RETA vs ERAS Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ERAS has a market cap of 5.8B. Regarding current trading prices, RETA is priced at $172.36, while ERAS trades at $18.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ERAS's P/E ratio is -42.11. In terms of profitability, RETA's ROE is +0.47%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, RETA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ERAS's competition here
RETA vs CDTX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RETA is priced at $172.36, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RETA's ROE is +0.47%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, RETA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check CDTX's competition here
RETA vs ABCM Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RETA is priced at $172.36, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RETA's ROE is +0.47%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RETA and ABCM have similar daily volatility (0.08).Check ABCM's competition here
RETA vs ISEE Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RETA is priced at $172.36, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RETA's ROE is +0.47%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RETA is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ISEE's competition here
RETA vs XENE Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, XENE has a market cap of 5.4B. Regarding current trading prices, RETA is priced at $172.36, while XENE trades at $68.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas XENE's P/E ratio is -14.66. In terms of profitability, RETA's ROE is +0.47%, compared to XENE's ROE of -0.49%. Regarding short-term risk, RETA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check XENE's competition here
RETA vs TVTX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, RETA is priced at $172.36, while TVTX trades at $56.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TVTX's P/E ratio is -257.23. In terms of profitability, RETA's ROE is +0.47%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, RETA is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check TVTX's competition here
RETA vs APLS Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RETA is priced at $172.36, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas APLS's P/E ratio is 38.35. In terms of profitability, RETA's ROE is +0.47%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RETA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check APLS's competition here
RETA vs CELC Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CELC has a market cap of 5.2B. Regarding current trading prices, RETA is priced at $172.36, while CELC trades at $107.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CELC's P/E ratio is -27.58. In terms of profitability, RETA's ROE is +0.47%, compared to CELC's ROE of -2.45%. Regarding short-term risk, RETA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CELC's competition here
RETA vs CRSP Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, RETA is priced at $172.36, while CRSP trades at $53.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CRSP's P/E ratio is -10.44. In terms of profitability, RETA's ROE is +0.47%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, RETA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CRSP's competition here
RETA vs DFTX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, RETA is priced at $172.36, while DFTX trades at $47.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas DFTX's P/E ratio is N/A. In terms of profitability, RETA's ROE is +0.47%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, RETA is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check DFTX's competition here
RETA vs LEGN Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, LEGN has a market cap of 5.1B. Regarding current trading prices, RETA is priced at $172.36, while LEGN trades at $27.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas LEGN's P/E ratio is -40.26. In terms of profitability, RETA's ROE is +0.47%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, RETA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check LEGN's competition here
RETA vs MANE Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MANE has a market cap of 5B. Regarding current trading prices, RETA is priced at $172.36, while MANE trades at $119.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MANE's P/E ratio is -38.07. In terms of profitability, RETA's ROE is +0.47%, compared to MANE's ROE of -0.84%. Regarding short-term risk, RETA is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MANE's competition here
RETA vs EWTX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, RETA is priced at $172.36, while EWTX trades at $45.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas EWTX's P/E ratio is -27.36. In terms of profitability, RETA's ROE is +0.47%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, RETA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check EWTX's competition here
RETA vs CAI Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CAI has a market cap of 4.8B. Regarding current trading prices, RETA is priced at $172.36, while CAI trades at $16.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CAI's P/E ratio is -93.45. In terms of profitability, RETA's ROE is +0.47%, compared to CAI's ROE of +0.06%. Regarding short-term risk, RETA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check CAI's competition here
RETA vs TERN Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RETA is priced at $172.36, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TERN's P/E ratio is -51.41. In terms of profitability, RETA's ROE is +0.47%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RETA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check TERN's competition here
RETA vs FOLD Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RETA is priced at $172.36, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RETA's ROE is +0.47%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RETA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check FOLD's competition here
RETA vs VKTX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, VKTX has a market cap of 4.5B. Regarding current trading prices, RETA is priced at $172.36, while VKTX trades at $38.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas VKTX's P/E ratio is -9.39. In terms of profitability, RETA's ROE is +0.47%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, RETA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check VKTX's competition here
RETA vs AKRO Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RETA is priced at $172.36, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RETA's ROE is +0.47%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, RETA is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check AKRO's competition here
RETA vs ACAD Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, RETA is priced at $172.36, while ACAD trades at $26.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ACAD's P/E ratio is 12.85. In terms of profitability, RETA's ROE is +0.47%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, RETA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ACAD's competition here
RETA vs ALPN Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RETA is priced at $172.36, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RETA's ROE is +0.47%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RETA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check ALPN's competition here
RETA vs OPT Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RETA is priced at $172.36, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas OPT's P/E ratio is -1.52. In terms of profitability, RETA's ROE is +0.47%, compared to OPT's ROE of +1.18%. Regarding short-term risk, RETA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check OPT's competition here
RETA vs NAMSW Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, NAMSW has a market cap of 4.2B. Regarding current trading prices, RETA is priced at $172.36, while NAMSW trades at $24.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas NAMSW's P/E ratio is -13.76. In terms of profitability, RETA's ROE is +0.47%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, RETA is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check NAMSW's competition here
RETA vs NAMS Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, NAMS has a market cap of 4.1B. Regarding current trading prices, RETA is priced at $172.36, while NAMS trades at $35.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas NAMS's P/E ratio is -22.18. In terms of profitability, RETA's ROE is +0.47%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, RETA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check NAMS's competition here
RETA vs MRTX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RETA is priced at $172.36, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RETA's ROE is +0.47%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RETA is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check MRTX's competition here
RETA vs DNLI Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, DNLI has a market cap of 4.1B. Regarding current trading prices, RETA is priced at $172.36, while DNLI trades at $25.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas DNLI's P/E ratio is -8.92. In terms of profitability, RETA's ROE is +0.47%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, RETA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check DNLI's competition here
RETA vs DNTH Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, DNTH has a market cap of 4.1B. Regarding current trading prices, RETA is priced at $172.36, while DNTH trades at $97.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas DNTH's P/E ratio is -23.63. In terms of profitability, RETA's ROE is +0.47%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, RETA is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check DNTH's competition here
RETA vs DYN Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, RETA is priced at $172.36, while DYN trades at $23.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas DYN's P/E ratio is -7.27. In terms of profitability, RETA's ROE is +0.47%, compared to DYN's ROE of -0.58%. Regarding short-term risk, RETA is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check DYN's competition here
RETA vs TNGX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, RETA is priced at $172.36, while TNGX trades at $31.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TNGX's P/E ratio is -37.42. In terms of profitability, RETA's ROE is +0.47%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, RETA is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check TNGX's competition here
RETA vs CPRX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, RETA is priced at $172.36, while CPRX trades at $31.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CPRX's P/E ratio is 11.32. In terms of profitability, RETA's ROE is +0.47%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RETA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check CPRX's competition here
RETA vs TLX Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, RETA is priced at $172.36, while TLX trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas TLX's P/E ratio is -605.43. In terms of profitability, RETA's ROE is +0.47%, compared to TLX's ROE of -0.02%. Regarding short-term risk, RETA is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check TLX's competition here
RETA vs RYZB Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RETA is priced at $172.36, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RETA's ROE is +0.47%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RETA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check RYZB's competition here
RETA vs CBAY Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RETA is priced at $172.36, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RETA's ROE is +0.47%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RETA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RETA.Check CBAY's competition here
RETA vs ELVN Comparison July 2026
RETA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RETA stands at 6.6B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, RETA is priced at $172.36, while ELVN trades at $51.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RETA currently has a P/E ratio of -66.29, whereas ELVN's P/E ratio is -30.59. In terms of profitability, RETA's ROE is +0.47%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, RETA is less volatile compared to ELVN. This indicates potentially lower risk in terms of short-term price fluctuations for RETA.Check ELVN's competition here